Residual risk in heart failure and the need for simultaneous implementation and innovation

Kaneez Fatima¹, Javed Butler^{2

3}, Gregg C Fonarow⁴

Affiliations

¹ Department of Research, Baylor Scott and White Research Institute, Dallas, TX, USA.
² Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
³ Baylor Scott and White Research Institute, Dallas, TX, USA.
⁴ Division of Cardiology, Department of Medicine, University of California, Los Angeles, CA, USA.

Free article

Kaneez Fatima et al. Eur J Heart Fail. 2023 Sep.

Free article

. 2023 Sep;25(9):1477-1480.

doi: 10.1002/ejhf.3005. Epub 2023 Aug 30.

Kaneez Fatima¹, Javed Butler^{2

3}, Gregg C Fonarow⁴

¹ Department of Research, Baylor Scott and White Research Institute, Dallas, TX, USA.
² Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
³ Baylor Scott and White Research Institute, Dallas, TX, USA.
⁴ Division of Cardiology, Department of Medicine, University of California, Los Angeles, CA, USA.

No abstract available

References

1. Greene SJ, Butler J, Fonarow GC. Contextualizing risk among patients with heart failure. JAMA. 2021;326:2261-2262. https://doi.org/10.1001/jama.2021.20739
1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. https://doi.org/10.1056/NEJMoa2107038
1. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-1098. https://doi.org/10.1056/NEJMoa2206286
1. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240-1247. https://doi.org/10.1001/jama.294.10.1240
1. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:2365-2383. https://doi.org/10.1016/j.jacc.2019.02.015